FENC,Fennec Pharmaceuticals Inc. | Healthcare

Healthcare

FENC

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Fennec Pharmaceuticals Inc.FENC

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

Market Cap

139.63M

Revenue (ttm)

47.54M

Net Income (ttm)

-436,000

Shares Out

27.59M

EPS (ttm)

-0.02

PE Ratio

n/a

Forward PE

73.09

Dividend

n/a

Ex-Dividend Date

n/a

Volume

n/a

Open

5.12

Previous Close

5.01

Day's Range

4.97 - 5.12

52-Week Range

3.96 - 10.92

Beta

0.32

Analysts

Strong Buy

Price Target

14.00 (+176.68%)

Earnings Date

May 13, 2025

Description >

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company.

The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients.

It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Latest News >

Else Nutrition Raises US$2 Million Through Unit Offering

Jul 8, 2024

07:06 AM EDT, 07/08/2024 (MT Newswires) -- Else Nutrition Holdings ( BABYF ) over the weekend said it raised US$2 million selling 13.2 million units at US$0.151 per unit. Each unit consists of one Else Nutrition ( BABYF ) common share and one common share purchase warrant exercisable to acquire one common share at a price of US$0.151 until July...

Eli Lilly to buy bowel disease drug developer Morphic for $3.2 bln

Jul 8, 2024

July 8 (Reuters) - Eli Lilly ( LLY ) will acquire Morphic Holding ( MORF ) for $3.2 billion, the companies said on Monday, giving the U.S. drugmaker access to an experimental drug for inflammatory bowel disease. Shares of drug developer Morphic ( MORF ) surged 76% to $56.15 premarket on Lilly's offer of $57 per share, which represents a...

Vista Outdoor Says Kinetic Group Purchase Price Raised by Czechoslovak Group to $2.1 Billion

Jul 8, 2024

07:03 AM EDT, 07/08/2024 (MT Newswires) -- Vista Outdoor ( VSTO ) said Monday that it entered an amendment to the merger agreement with Czechoslovak Group, increasing the purchase price for The Kinetic Group business by $100 million to $2.1 billion. The amendment also increases the cash consideration payable to Vista Outdoor ( VSTO ) stockholders by $3 per share...

Bitcoin miner Bitfarms taps insider Ben Gagnon for CEO role

Jul 8, 2024

July 8 (Reuters) - Canada-based bitcoin miner Bitfarms ( BITF ) said on Monday it has appointed insider Ben Gagnon as its new chief executive officer. ...